Length of Stay Comparison Between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study

Overview

Journal Thrombosis

Date 2016 Feb 17

PMID 26881071

Citations 9

Authors

Kirsten M Roberts

Tamara B Knight

Eimeira Padilla-Tolentino

Manasa Murthy

Evan J Peterson

Affiliations

Soon will be listed here.

Abstract

Background. Trials have shown that novel oral anticoagulants may decrease length of stay versus warfarin. A comparison of length of stay in the treatment of pulmonary embolism (PE) has not been performed outside post hoc analysis of a large clinical trial. Objective. To evaluate if rivaroxaban decreases length of stay compared to warfarin plus enoxaparin in the treatment of PE. Methods. This was a multicenter, retrospective, observational cohort study. Patients were identified based on discharge diagnosis of PE and were excluded if they received anticoagulants prior to admission and had additional indications for anticoagulation or reduced creatinine clearance. The primary endpoint was length of stay. Secondary endpoints included time from initial dose of oral anticoagulant to discharge and length of stay comparison between subgroups. Results. Inclusion criterion was met by 158 patients (82 warfarin, 76 rivaroxaban). The median length of stay was 4.5 days (interquartile range [IQR], 2.7, 5.9) in the warfarin group and 1.8 days (IQR, 1.2, 3.7) in the rivaroxaban group (P < 0.001). Time interval from first dose of oral anticoagulant to discharge was shorter with rivaroxaban (P < 0.001). Conclusions. Patients given rivaroxaban had decreased length of stay versus those given warfarin plus enoxaparin for the treatment of PE.

Citing Articles

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care.

Peacock W, Coleman C, Wells P, Fermann G, Wang L, Baser O J Health Econ Outcomes Res. 2020; 6(3):160-173.

PMID: 32685588 PMC: 7299482. DOI: 10.36469/9936.

Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings.

Trocio J, Rosen V, Gupta A, Dina O, Vo L, Hlavacek P Clinicoecon Outcomes Res. 2018; 11:23-49.

PMID: 30588051 PMC: 6305128. DOI: 10.2147/CEOR.S179080.

Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.

Badreldin H J Thromb Thrombolysis. 2018; 46(1):16-21.

PMID: 29626281 DOI: 10.1007/s11239-018-1661-y.

Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer.

Kim H, Vargo J, Beriwal S, Clump D, Ohr J, Ferris R Head Neck. 2018; 40(8):1743-1751.

PMID: 29537684 PMC: 7409550. DOI: 10.1002/hed.25142.

Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis.

Groetzinger L, Miller T, Rivosecchi R, Smith R, Gladwin M, Rivera-Lebron B Clin Appl Thromb Hemost. 2018; 24(6):908-913.

PMID: 29455567 PMC: 6714714. DOI: 10.1177/1076029618755311.

References

Knight K, Wong J, Hauch O, Wygant G, Aguilar D, Ofman J . Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health. 2005; 8(3):191-200. DOI: 10.1111/j.1524-4733.2005.04026.x. View

van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing A . Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 2014; 30(5):829-37. DOI: 10.1185/03007995.2013.879439. View

Barritt D, Jordan S . Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet. 1960; 1(7138):1309-12. DOI: 10.1016/s0140-6736(60)92299-6. View

Dalen J . Pulmonary embolism: what have we learned since Virchow?: treatment and prevention. Chest. 2002; 122(5):1801-17. DOI: 10.1378/chest.122.5.1801. View

Buller H, Decousus H, Grosso M, Mercuri M, Middeldorp S, Prins M . Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15):1406-15. DOI: 10.1056/NEJMoa1306638. View

Ageno W, Gallus A, Wittkowsky A, Crowther M, Hylek E, Palareti G . Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e44S-e88S. PMC: 3278051. DOI: 10.1378/chest.11-2292. View

Dasta J, Pilon D, Mody S, Lopatto J, Laliberte F, Germain G . Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. Thromb Res. 2015; 135(2):303-10. DOI: 10.1016/j.thromres.2014.11.024. View

Schulman S, Kakkar A, Goldhaber S, Schellong S, Eriksson H, Mismetti P . Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2013; 129(7):764-72. DOI: 10.1161/CIRCULATIONAHA.113.004450. View

Spyropoulos A, Lin J . Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007; 13(6):475-86. PMC: 10437642. DOI: 10.18553/jmcp.2007.13.6.475. View

10.

Agnelli G, Buller H, Cohen A, Curto M, Gallus A, Johnson M . Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9):799-808. DOI: 10.1056/NEJMoa1302507. View

11.

Laliberte F, Pilon D, Raut M, Nelson W, Olson W, Germain G . Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?. Curr Med Res Opin. 2013; 30(4):645-53. DOI: 10.1185/03007995.2013.867843. View

12.

Bookhart B, Haskell L, Bamber L, Wang M, Schein J, Mody S . Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ. 2014; 17(10):691-5. DOI: 10.3111/13696998.2014.946993. View

13.

Lin J, Lingohr-Smith M, Kwong W . Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective. J Manag Care Pharm. 2014; 20(2):174-86. PMC: 10438350. DOI: 10.18553/jmcp.2014.20.2.174. View

14.

Buller H, Prins M, Lensin A, Decousus H, Jacobson B, Minar E . Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14):1287-97. DOI: 10.1056/NEJMoa1113572. View

15.

Mahan C, Borrego M, Woersching A, Federici R, Downey R, Tiongson J . Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012; 108(2):291-302. DOI: 10.1160/TH12-03-0162. View

16.

Beckman M, Hooper W, Critchley S, Ortel T . Venous thromboembolism: a public health concern. Am J Prev Med. 2010; 38(4 Suppl):S495-501. DOI: 10.1016/j.amepre.2009.12.017. View

17.

Patel A, Ogden K, Mody S, Bookhart B . The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. J Med Econ. 2015; 18(5):323-32. DOI: 10.3111/13696998.2014.1001850. View